T2 Biosystems, Inc. Stock price

Equities

TTOO

US89853L3024

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 03:59:25 2024-02-23 pm EST 5-day change 1st Jan Change
5.45 USD -0.55% Intraday chart for T2 Biosystems, Inc. 0.00% -13.15%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * 7.2M Sales 2024 * 10.3M Capitalization 22M
Net income 2023 * -48M Net income 2024 * -43M EV / Sales 2023 * 3.06 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 2.14 x
P/E ratio 2023 *
-0.29 x
P/E ratio 2024 *
-0.85 x
Employees 158
Yield 2023 *
-
Yield 2024 *
-
Free-Float 96.89%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : T2 Biosystems, Inc., Q4 2023 Earnings Call, Feb 15, 2024
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia CI
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care Stocks Steady in Afternoon Trading MT
T2 Biosystems Gets FDA Clearance for Expanded T2Bacteria Panel; Shares Rise MT
T2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria Panel DJ
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel CI
T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group Pilot Study for Pneumonia Patients CI
T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors CI
T2 Biosystems, Inc. Announces FDA 510(K) Submission to Expand Use of the FDA-Cleared T2candida Panel to Include Pediatric Testing CI
T2 Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference CI
T2 Biosystems, Inc. Announces Amendment and Extension of CRG Term Loan Agreement CI
T2 Biosystems Submits 510(k) to Add Detection of Acinetobacter Baumannii to List of Pathogens Covered by T2Bacteria Panel MT
Transcript : T2 Biosystems, Inc., Q3 2023 Earnings Call, Oct 12, 2023
More news
1 day-0.55%
Current month+21.11%
1 month+32.60%
3 months+33.25%
6 months-85.17%
Current year-13.15%
More quotes
1 week
5.08
Extreme 5.08
5.66
1 month
4.13
Extreme 4.13
6.95
Current year
3.81
Extreme 3.81
6.95
1 year
3.36
Extreme 3.36
70.00
3 years
3.36
Extreme 3.36
11 939.00
5 years
3.36
Extreme 3.36
26 900.00
10 years
3.36
Extreme 3.36
122 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-01-07
Director of Finance/CFO 65 18-01-29
Chief Tech/Sci/R&D Officer 59 13-12-31
Members of the board TitleAgeSince
Director/Board Member 74 14-06-30
Director/Board Member 74 16-09-20
Director/Board Member 63 20-06-13
More insiders
Date Price Change Volume
24-02-23 5.42 -1.09% 92,464
24-02-22 5.48 -1.26% 95,238
24-02-21 5.55 +0.54% 137,670
24-02-20 5.52 +1.28% 142,978

Delayed Quote Nasdaq, February 23, 2024 at 03:59 pm EST

More quotes
T2 Biosystems, Inc. is an in-vitro diagnostics company. The Company is focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. The Company is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its primary commercial products include the T2Candida Panel and the T2Bacteria Panel. Its T2Candida Panel is a direct-from-blood test that identifies the lethal form of common bloodstream infections that cause sepsis and candidemia. Its T2Bacteria Panel is a direct-from-blood test that detects certain bacterial pathogens associated with sepsis. Its primary commercial products also include the T2Dx Instrument, the T2Resistance Panel, and the T2SARS-CoV-2 Panel.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.42 USD
Average target price
4 USD
Spread / Average Target
-26.20%
Consensus
  1. Stock
  2. Equities
  3. Stock T2 Biosystems, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW